Brown Cancer Center researchers Robert Mitchell and John Trent discovered that 4-IPP, a novel small molecule compound, exhibits anti-tumor activity by blocking tumor-specific angiogenesis, and thus far has demonstrated a favorable safety profile in laboratory studies. The University of Louisville researchers have shown in the laboratory that 4-IPP could serve as front-line therapy against bulk tumors and reduce the risk of recurrence of primary tumors or eventual metastasis.
In addition, while initially targeted for development in oncology, 4-IPP has subsequently been evaluated for its potential to address various unmet medical needs in autoimmune related diseases such as rheumatoid arthritis, lupus and multiple sclerosis.
Randall Riggs, president & CEO of Advanced Cancer Therapeutics (ACT), said: “We are very excited to license this small molecule compound, 4-IPP, and its related compounds that could have utility in both oncology and various autoimmune diseases.”